Nevirapine induced mitochondrial dysfunction in HepG2 cells.

Area of Science:

• Biochemistry
• Hepatology
• Pharmacology

Background:

• Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used for HIV-1 treatment.
• NVP can cause severe hepatotoxicity, particularly in patients co-infected with hepatitis C virus.
• The precise mechanism of NVP-induced liver injury remains largely unknown.

Purpose of the Study:

• To investigate the impact of Nevirapine on protein expression in liver cells.
• To elucidate the molecular mechanisms underlying NVP-associated hepatotoxicity using a proteomic approach.

Main Methods:

• HepG2 liver cells were treated with NVP.
• Proteomic analysis was performed using two-dimensional gel electrophoresis to identify differentially expressed proteins.
• Mitochondrial function was assessed via mitotracker staining and RT-PCR analysis of mitochondrially encoded genes.

Main Results:

• Proteomic analysis identified 33 differentially regulated proteins, with 13 (nearly 40%) being mitochondrial proteins.
• RT-PCR confirmed significant up-regulation of three mitochondrially encoded genes in NVP-treated cells.
• Mitochondrial dysfunction was observed even at sub-optimal NVP concentrations.

Conclusions:

• Nevirapine treatment leads to significant mitochondrial dysregulation in liver cells.
• Mitochondrial impairment is a key mechanism contributing to NVP-induced hepatotoxicity.
• Further research is warranted to explore therapeutic strategies targeting mitochondrial pathways.